Australia is eagerly awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://fraserwlsh669127.illawiki.com/2644433/retatrutide_australia_a_new_hope_for_obesity_treatment